170
Views
4
CrossRef citations to date
0
Altmetric
Cancer

Ingenol mebutate for the treatment of actinic keratosis: effectiveness and safety in 246 patients treated in real-life clinical practice

&
Pages 393-399 | Received 03 Jul 2017, Accepted 06 Sep 2017, Published online: 08 Nov 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Nevena Skroza, Nicoletta Bernardini, Ilaria Proietti & Concetta Potenza. (2018) Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice. Therapeutics and Clinical Risk Management 14, pages 1879-1885.
Read now

Articles from other publishers (3)

Vincent A. Ricigliano, Vincent P. Sica, Sonja L. Knowles, Nicole Diette, Dianella G. Howarth & Nicholas H. Oberlies. (2020) Bioactive diterpenoid metabolism and cytotoxic activities of genetically transformed Euphorbia lathyris roots. Phytochemistry 179, pages 112504.
Crossref
Alise Balcere, Māra Rone Kupfere, Ingrīda Čēma & Angelika Krūmiņa. (2019) Prevalence, Discontinuation Rate, and Risk Factors for Severe Local Site Reactions with Topical Field Treatment Options for Actinic Keratosis of the Face and Scalp. Medicina 55:4, pages 92.
Crossref
Maria Lluria-Prevatt, Sally E. Dickinson & David S. Alberts. 2019. Fundamentals of Cancer Prevention. Fundamentals of Cancer Prevention 405 472 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.